Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Bio-Path Stock Performance

Bio-Path stock opened at $0.17 on Tuesday. Bio-Path has a 12 month low of $0.12 and a 12 month high of $7.67. The business has a 50 day simple moving average of $0.56 and a 200-day simple moving average of $0.81.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.